Factors that influence exhaled nitric oxide in Italian schoolchildren

Fabio Cibella, MD*; Giuseppina Cuttitta, MD†; Stefania La Grutta, MD‡; Giovanni Passalacqua, MD§; and Giovanni Viegi, MD*||

Background: Conflicting results exist about the meaning of exhaled nitric oxide (eNO) in epidemiologic studies, mainly because of the numerous factors that may affect the measurement.

Objectives: To evaluate the role of the factors that influence eNO levels in a sample of schoolchildren with or without respiratory diseases. We studied 335 schoolchildren, ages 10 to 16 years, from 8 schools in Palermo, Italy. After a respiratory questionnaire was completed, spirometry, skin tests, and eNO measurements were performed.

Results: Among 335 children, 13.7% reported symptoms of bronchial asthma, 46.9% reported symptoms of rhinitis, and 39.4% were asymptomatic. The ratio of forced expiratory volume in 1 second to forced vital capacity was 87.6% (SD, 6.4%) in the bronchial asthma group, 90.6% (SD, 5.0%) in the rhinitis group, and 90.4% (SD, 5.1%) in the asymptomatic group (P < .002). Atopic children constituted 52.2% of the bronchial asthma group, 40.1% of the rhinitis group, and 28.8% of the asymptomatic group. Among atopic children, 102 (82%) had a positive skin test result for Dermatophagoides. Median eNO was 12.6 ppb in nonatopic children and 21.2 ppb in atopic children (P < .001, by Mann-Whitney U test). Among asymptomatic children, atopic children had significantly higher eNO levels than did nonatopic children (P < .001). In nonatopic children, no difference was found in log transformation eNO among healthy, rhinitic, or asthmatic children. Log transformation eNO increased with the number of positive skin test results (P < .001). Atopy, asthma, male sex, and indoor allergens were predictors of increased eNO in a logistic model.

Conclusions: Atopy (in particular, sensitization to indoor and perennial allergens) is strongly associated with higher eNO levels. Such association is enhanced by asthma.

INTRODUCTION

Exhaled nitric oxide (eNO) has been proposed as a noninvasive marker of airway inflammation in asthma and respiratory allergy, and its use is currently increasing, in view of its relatively simple procedure. The latter represents an additional advantage, especially in the pediatric population. Furthermore, the measurement of eNO has been suggested as a valuable tool in adjusting asthma therapy according to inflammation. Increased levels of eNO have been found in asthmatic children1 and in asymptomatic atopic children.2-4 Consequently, it has been suggested that the relation between asthma and increased eNO levels may be mediated by atopy itself.5 This suggestion emphasizes the key role of atopic inflammation in determining an increase in eNO production for allergic diseases such as asthma and rhinitis.6,7

Nevertheless, some conflicting results exist about the meaning of eNO measures in epidemiologic studies. In fact, some authors did not find any difference in eNO levels between atopic and nonatopic healthy individuals.1,8 Conversely, other studies demonstrated a linear or dose-response relation between the degree of skin test positivity and eNO levels.2-4 The relative weight of some factors (atopy, clinical disease, number of positive skin test results) remains to be determined. The aim of the present study was to identify the determinants of high eNO levels in a sample of schoolchildren with and without respiratory disease.

METHODS

Patient Population

This was a cross-sectional study conducted in a sample of schoolchildren, ages 10 to 16 years, from 8 junior high schools in Palermo, Southern Italy, in 2004. The whole student population of the 8 schools was 4,711 children. Among them, we randomly selected 1,177 children for the study (1 for every 4). One hundred twenty-seven children did not obtain parental consent or were not present at school on the day of the study. Thus, 1,050 children completed the respiratory health questionnaire6 and underwent lung function testing and skin prick testing at school. One third of 1,050 children (1 of every 3 children; total, 350) were selected for eNO testing in our laboratory. Fifteen children were excluded because of recent upper or lower respiratory tract infections.
or insufficient cooperation in performing eNO measures. Thus, we obtained eNO measurements in 335 children. Except for asthma, no other chronic pulmonary disease was reported, and no child was taking oral or inhaled steroids. The study was approved by the institutional ethics committee. All parents of the children signed a written informed consent form. According to Italian law, respect for individual privacy concerning clinical data was granted.

Study Parameters

A history of physician-diagnosed asthma was defined as a positive answer to the question, “Have you ever had asthma diagnosed by a physician?” Rhinitis was defined as a positive answer to the question, “Have you ever had sneezing, or runny, or blocked nose apart from common cold or flu?” Based on these criteria, children were subdivided into 3 subgroups: asthmatic children, rhinitic children, and control children, that is, children without asthma or rhinitis.

Skin tests were performed according to international recommendations with a standard panel, including Dermatophagoides mix, grass mix, Parietaria judaica, Compositae mix, olive, dog and cat dander, Alternaria, and Blattella germanica, plus a positive (histamine 1%) and a negative (saline) control (Stallergerënes Italia S.r.l., Milan, Italy). The positivity was measured after 15 minutes, and reactions were considered positive if the wheal was 3 mm or greater in its larger diameter, in the presence of a negative reaction to the saline control. Atopy was defined as the presence of at least 1 positive skin prick test result. Children were grouped into 3 different groups according to the number of the positive skin prick test results: nonatopic, 1 positive skin prick test result, or 2 or more positive skin prick test results.

Height and weight were measured in all the children, and body mass index was calculated as weight in kilograms divided by height in meters squared. Pulmonary function tests were performed with the use of a portable spirometer (MicroLoop, Micro Medical; Chatham Maritime, Kent, England). Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured according to American Thoracic Society guidelines, and the best (largest sum of FVC and FEV1) of 3 technically acceptable and reproducible maneuvers was retained.

Nitric Oxide Measurements

On a different day, fractional eNO concentrations were measured in our medical laboratory by a chemiluminescence analyzer connected to a computerized system (NIOX; Acrine AB, Stockholm, Sweden). The instrument had a sensitivity of 1.5 ppb, a detection range of 0 to 200 ppb, and a response time less than 0.8 second. The instrument was calibrated with a certified NO gas mixture. The online single exhalation technique provided automatic control of exhalation to a constant flow rate of 50 mL/s, according to American Thoracic Society recommendations. During exhalation, positive pressure provided closure of the velum, preventing contamination of the sample with nasal NO. The mean eNO value of 3 valid measurements was recorded for each participant.

Table 1. Descriptive Data of the Total Sample and Study Population

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total sample (n = 1,050)</th>
<th>Study population (n = 335)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male, No.</td>
<td>573/477</td>
<td>191/144</td>
</tr>
<tr>
<td>Age, mean (range), y</td>
<td>12.2 (10–17)</td>
<td>12.1 (10–16)</td>
</tr>
<tr>
<td>Asthmatic, No. (%)</td>
<td>129 (12.3)</td>
<td>46 (13.7)</td>
</tr>
<tr>
<td>Rhinitic, No. (%)</td>
<td>491 (46.8)</td>
<td>157 (46.9)</td>
</tr>
<tr>
<td>Control, No. (%)</td>
<td>430 (40.9)</td>
<td>132 (39.4)</td>
</tr>
<tr>
<td>Atopy, No. (%)</td>
<td>329 (31.3)</td>
<td>125 (37.3)</td>
</tr>
<tr>
<td>FVC, mean (SD), L</td>
<td>3.06 (0.64)</td>
<td>2.97 (0.58)</td>
</tr>
<tr>
<td>FVC, mean (SD), % predicted</td>
<td>98.7 (11.8)</td>
<td>98.0 (11.5)</td>
</tr>
<tr>
<td>FEV1, mean (SD), L</td>
<td>2.74 (0.55)</td>
<td>2.66 (0.49)</td>
</tr>
<tr>
<td>FEV1, mean (SD), % predicted</td>
<td>99.0 (11.6)</td>
<td>98.7 (10.8)</td>
</tr>
<tr>
<td>FEV1/FVC, mean (SD), %</td>
<td>89.7 (5.7)</td>
<td>90.1 (5.34)</td>
</tr>
<tr>
<td>FEV1/FVC, mean (SD), % predicted</td>
<td>100.5 (6.2)</td>
<td>100.9 (5.9)</td>
</tr>
</tbody>
</table>

Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second.

Table 2. Atopy, Respiratory Function, and eNO Data for Each Clinical Subgroup

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control patients (n = 132)</th>
<th>Rhinitic patients (n = 157)</th>
<th>Asthma patients (n = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic children, No. (%)</td>
<td>38 (28.8)a</td>
<td>63 (40.1)a</td>
<td>24 (52.2)a</td>
</tr>
<tr>
<td>FEV1/FVC, mean (SD), %</td>
<td>90.4 (5.10)</td>
<td>90.6 (5.03)</td>
<td>87.6 (6.41)b</td>
</tr>
<tr>
<td>FEV1/FVC, mean (SD), % predicted</td>
<td>101.5 (5.5)</td>
<td>101.3 (5.5)</td>
<td>97.9 (7.0)b</td>
</tr>
<tr>
<td>eNO in atopic children, median (range), ppb</td>
<td>17.4 (5.5–95.2)</td>
<td>19.1 (5.8–92.5)</td>
<td>48.8 (8.2–88.0)c</td>
</tr>
<tr>
<td>eNO in nonatopic children, median (range), ppb</td>
<td>13.1 (3.0–71.0)</td>
<td>12.6 (2.8–71.8)</td>
<td>11.0 (3.8–28.9)</td>
</tr>
</tbody>
</table>

Abbreviations: eNO, exhaled nitric oxide; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second.

a P = .01 (χ² test).
b P = .002 compared with controls and rhinitic children (analysis of variance).
c P < .001 compared with controls and rhinitic children (Mann-Whitney U test). Unless otherwise indicated, differences are not significant.
Statistical Analyses
Analysis of variance and frequency distribution tables (\(\chi^2\) test) for parametric variables were performed. Because the distribution of eNO values was highly skewed, results were expressed as values after natural log transformation (ln eNO). Correlations among variables were investigated by simple linear regression analysis. To study the independent variables able to influence the risk for elevated eNO levels, eNO was dichotomized at the level of the 75th percentile and the logistic regression model was used to explore the relation between the dependent variable (eNO) and independent variables (atopy, asthma, and sex), adjusting for confounding variables (pulmonary function, lung size, and height). For this purpose, continuous independent variables were dichotomized at the level of the 50th percentile of their distribution. All computations were performed with the use of the StatView statistical software package (SAS Institute Inc, Cary, North Carolina). \(P < .05\) was selected as statistically significant.

RESULTS

Participating in the study, 335 children were included. The majority of the children were male (62.3%). The age distribution of the children was as follows: 10.4% were under 5 years of age, 14.3% were 5 to 9 years, 26.3% were 10 to 14 years, 32.7% were 15 to 19 years, and 16.1% were older than 20 years. The distribution of children by age was similar in all groups (Table 1). The total sample consisted of 335 children (105 males and 230 females). The age distribution of the children was as follows: 10.4% were under 5 years of age, 14.3% were 5 to 9 years, 26.3% were 10 to 14 years, 32.7% were 15 to 19 years, and 16.1% were older than 20 years. The distribution of children by age was similar in all groups (Table 1).

As indicated in Table 2, 46 of 335 children (13.7%) reported asthma with or without rhinitis, 157 (46.9%) reported rhinitis alone, and the remaining 132 (39.4%) reported neither asthma nor rhinitis. The prevalence of asthma was significantly higher in children with multiple positive skin test results compared with nonatopic children. The prevalence of atopy was higher in children with multiple positive skin test results compared with nonatopic children. The prevalence of atopy was significantly higher in children with multiple positive skin test results compared with nonatopic children.

As mentioned herein, children were divided into 3 different groups according to skin positivity (atopic, 1 positive skin test result, and 2 or more positive skin test results). The level of ln eNO was significantly increased in children with 1 positive skin test result and even higher in children with multiple positive skin test results compared with nonatopic children. Differences in eNO levels among the 3 skin prick groups are shown in Figure 2. The linear correlation between ln eNO and number of positive skin test results (as continuous variable) was statistically significant (\(P < .001\), both in the
and height, FVC, FEV1 (percentage of predicted), FEV1/FVC, find any relation between ln eNO (as the dependent variable).

To evaluate the inter-

ment for FEV1/FVC, FVC, and height. To evaluate the inter-

Abbreviations: CI, confidence interval; OR, odds ratio.

(Table 3) atopy and cat dander) are associated with significantly increased eNO levels. Furthermore, the highest eNO levels are obs-

erved in atopic children with physician-diagnosed asthma. In particular, even in the subgroup of asymptomatic individuals, atopic individuals have significantly higher eNO levels (the median eNO was 33% higher in asymptomatic atopic children than in nonatopic children). This finding suggests that atopy per se is able to significantly influence eNO levels. Similar results were previously reported in both adults and children. However, other studies did not find a relation between atopy and eNO levels in children. In particular, Latzin et al failed to demonstrate a relation between atopy and eNO levels in 4- to 18-year-old healthy children. A possible explanation for these conflicting results might be found in the dimension of the studied sample, the different prevalence of atopic children in the study samples, and the different age distributions. In fact, in our study, the prevalence of atopy was 29% among asymptomatic children, and the age range was 10 to 16 years: The corresponding figures in the study by Latzin et al were 46% and 4 to 18 years, respectively.

We found that boys have significantly higher eNO levels than do girls. This result is in agreement with the works of Barreto et al and Wong et al, who recently demonstrated a sex difference in eNO levels in schoolchildren. Similarly, Nordvall et al, in a large population sample, found a significantly higher eNO in boys than in girls. The authors attributed this finding to a possible role of larger lung volumes in boys. However, after correcting also for FVC, as an index of lung volume, in our logistic model, we found that male sex maintains a significant effect in increasing eNO values. Nevertheless, controversial results exist on the relation between sex and eNO levels; in fact, in some studies no association was found between sex and eNO. In the study by Malmberg et al, the authors demonstrated that height was a strong predictor of increased eNO in healthy children. The latter association was not found in our study. The difference may be due to the wider age range (7–16 years) in the study by Malmberg et al, producing a wider height range. Similarly, Buchvald et al found a significant correlation between eNO levels and age. We did not find such correlation. Once more, this difference may be explained by the wider age range (4–17 years) in the study by Buchvald et al.

Our results show that children with rhinitis alone do not have eNO values significantly different from control children, both in atopic and nonatopic subgroups (Fig 1). Conversely, Jouaville et al demonstrated that atopic children with rhinitis have higher eNO levels than do atopic control children. This difference may be explained by the methodologic differences in eNO measurement and by the smaller sample size in the study by Jouaville et al. Buchvald et al in a sample of 405 children ages 4 to 17 years, showed a significant difference between rhinitic and control children. In the latter study, however, the presence of atopy was evaluated on the basis of self-reported symptoms.

It is noteworthy that asthmatic, nonatopic children show eNO levels close to those of nonatopic rhinitic and asymp-

tomatic children. This finding is in agreement with the study.
by Ludviksdottir et al., who did not observe any significant difference in eNO between nonasthmatic control patients and nonatopic adult asthmatic patients. Furthermore, when rhinitis and especially asthma were associated with atopy, we found much greater eNO levels; in fact, median eNO in atopic, asthmatic patients was approximately 4-fold higher than the level of nonatopic, asthmatic patients (Table 2). Thus, the association of asthma and atopy appears to be the most consistent predictor of increased eNO level. A similar result was obtained by Frank et al., who found that the eNO geometric mean was significantly higher in children with atopic asthma than in nonatopic asthmatic children. These findings further support the hypothesis that in children atopy is a major determinant of increased eNO levels, mainly when associated with clinical manifestation of asthma. In other words, atopy and asthma appear as cofactors in determining elevated eNO levels.

In the present study, we also found that eNO level increased with the number of positive skin prick test results regardless of clinical status; in fact, when the number of individual positive skin prick test results was used as the continuous independent variable, the linear regression with eNO (as the dependent one) was significant both in the overall sample and in each subgroup (ie, allergic, rhinitic, and control children). This result is consistent with previous studies demonstrating the effect of the number of positive skin test results on the level of eNO. In particular, Franklin et al. found that in healthy children eNO levels were higher in those with a positive skin prick test result and even higher in children with more than 1 positive skin test result, suggesting that allergen sensitization may play a significant role in elevating eNO production in the respiratory tract.

The logistic analysis model also showed that after adjusting for confounding variables, only sensitization to Dermatophagoides and cat dander influence eNO levels. Similarly, Leuppi et al. showed that in atopic children, an increased eNO level is associated with sensitization to perennial allergens but not with seasonal allergens. In addition, Barreto et al. reported no difference in eNO levels between nonatopic and atopic children sensitized to grass pollen. Thus, sensitization to indoor perennial allergens appears to affect eNO production in the respiratory tract, possibly through long-lasting inflammatory stimuli, regardless of clinical respiratory manifestations. This finding is in agreement with the study by Gratzioiu et al., who suggested that eNO levels mainly reflect the allergic origin of inflammation in the airways.

In conclusion, atopic status is strongly associated with high eNO levels, even in asymptomatic individuals. The relation between atopy and eNO levels indicates that eNO measurements may help to clarify the relevant role of sensitization in the complex interplay of multiple factors determining the translation into clinical allergy. Furthermore, this finding also helps to address the problem of asymptomatic allergen sensitization vs clinical allergy, also envisaging the possible role of eNO measurement as a noninvasive screening test for early detection of individuals prone to have clinical allergy. In particular, the sensitization to indoor perennial allergens appears to be one of the main determinants of high eNO levels. Furthermore, the eNO levels were positively correlated with the number of positive skin prick test results. Consequently, we recommend performing eNO measurements in epidemiologic studies on respiratory diseases in children, taking into account the individual’s atopic status. The development of new portable instruments for eNO monitoring opens new perspectives to widespread use of such measurements in epidemiology.

ACKNOWLEDGMENTS
We thank Dr Marzia Simoni for kind support in statistical analysis and Dr Roberto Perissin and Dr Gabriele Nicolini for technical support. The allergens for skin prick tests were kindly provided by Dr Franco Frati (Stallergenes Italia S.r.l., Milan, Italy). We also express our gratitude to Dr Anna Lucania and Dr Girolamo Panasci for excellent medical assistance.

REFERENCES


Requests for reprints should be addressed to:
Fabio Cibella, MD
Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy” del C.N.R
via Ugo La Malfa, 153
90146 Palermo, Italy
E-mail: cibella@ibim.cnr.it